The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and others has doctors running scared, making it tough for everyone to sell drugs there.
Medtronic is setting up a de facto incubator in Singapore, planning to design, test and scale new business models for the developing world.
Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.
Non-profit International Vaccine Institute (IVI) has inked partnerships with Indian agencies as part of its drive to deepen ties to the country.
The owners of India's Gujarat Research Allopathic Foundation (GRAF) Laboratories see a future in nutraceuticals and are building a plant to realize that vision.
Johnson & Johnson is reorganizing its operations in China. Amid a government probe of corruption and pricing policies in the pharma industry, J&J has appointed a local chairman, Jesse Wu, to oversee all three of its Chinese operations--consumer health, devices and diagnostics, and pharmaceuticals.
As Chinese regulators crack down on device and drug companies, Johnson & Johnson is centralizing its leadership in the country, a move to increase oversight and profitability.
Covidien has made its first R&D foray into South Korea, opening a center to develop new technology, train local physicians and expand its share of a growing market.
Switzerland-based contract manufacturer Siegfried has decided to join those companies that are building in China, even as it expands other parts of its manufacturing operations.
Switzerland's Psi is reaching into India's clinical research market, opening up shop in the country and continuing its global expansion.